Compare Dollar General Corp. (DG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Sana Biotechnology Inc — how do they compare? Dollar General Corp. trades at $120.2 (market cap $26.49B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Dollar General Corp. is far larger — about 23.4× Sana Biotechnology Inc's market cap, and Dollar General Corp. pays a 1.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DG | SANA | |
|---|---|---|
Market Cap | $26.49B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $5.92 |
52-Week Low | $95.94 | $2.68 |
Enterprise Value | $40.93B | $1.05B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $119.65, down 2.24% amid broader market weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, trading below analyst consensus target of $128.45. Recent earnings beats and positive cash flow trends ($395M net in 2025) support the bullish case, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages.
Outlook remains positive given 52% analyst buy ratings and projected earnings growth, but investors face margin pressure and competitive threats from Walmart and Amazon. The stock offers value characteristics with upside to price targets, though same-store sales growth and cost management will be critical for sustained performance.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
